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Matsumoto and colleagues recently identified PEX26 as the gene responsible for complementation group 8 of the
peroxisome biogenesis disorders and showed that it encodes an integral peroxisomal membrane protein with a
single C-terminal transmembrane domain and a cytosolic N-terminus that interacts with the PEX1/PEX6 hetero-
dimer through direct binding to the latter. They proposed that PEX26 functions as the peroxisomal docking factor
for the PEX1/PEX6 heterodimer. Here, we identify new PEX26 disease alleles, localize the PEX6-binding domain
to the N-terminal half of the protein (aa 29–174), and show that, at the cellular level, PEX26 deficiency impairs
peroxisomal import of both PTS1- and PTS2-targeted matrix proteins. Also, we find that PEX26 undergoes alter-
native splicing to produce several splice forms—including one, PEX26-Dex5, that maintains frame and encodes an
isoform lacking the transmembrane domain of full-length PEX26 (PEX26-FL). Despite its cytosolic location, PEX26-
Dex5 rescues peroxisome biogenesis in PEX26-deficient cells as efficiently as does PEX26-FL. To test our observation
that a peroxisomal location is not required for PEX26 function, we made a chimeric protein (PEX26-Mito) with
PEX26 as its N-terminus and the targeting segment of a mitochondrial outer membrane protein (OMP25) at its
C-terminus. We found PEX26-Mito localized to the mitochondria and directed all detectable PEX6 and a fraction
of PEX1 to this extraperoxisomal location; yet PEX26-Mito retains the full ability to rescue peroxisome biogenesis
in PEX26-deficient cells. On the basis of these observations, we suggest that a peroxisomal localization of PEX26
and PEX6 is not required for their function and that the interaction of PEX6 with PEX1 is dynamic. This model
predicts that, once activated in an extraperoxisomal location, PEX1 moves to the peroxisome and completes the
function of the PEX1/6 heterodimer.
Introduction
Peroxisomes are ubiquitous, single-membrane–bound or-
ganelles that contain 50 enzymes and participate in a
variety of metabolic pathways. The importance of the
peroxisome in development and metabolism is highlighted
by inherited defects in peroxisome biogenesis in which
most or all of peroxisomal metabolic functions are defi-
cient (Wanders 2004a, 2004b). The clinical phenotype of
the peroxisome-biogenesis disorders (PBDs) varies widely
in severity and can be classified into two broad categories,
the Zellweger spectrum and rhizomelic chondrodysplasia
punctata (RCDP [MIM 215100]) (Gould et al. 2001).
The Zellweger spectrum includes at least three over-
lapping phenotypes that represent segments of a phe-
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notypic continuum, including Zellweger syndrome (ZS
[MIM 214100]) at the severe end, neonatal adrenoleu-
kodystrophy (NALD [MIM 202370]) as an intermediate
form, and infantile Refsum disease (IRD [MIM 266510])
at the mild end of the spectrum. Dysmorphic features,
neurological symptoms, hepatic disease, and skeletal ab-
normalities in varying degrees are common to all three
(Gould et al. 2001). Reflecting the complexity of peroxi-
some assembly, somatic-cell-hybridization studies show
that PBDs are genetically heterogeneous, with at least 13
human complementation groups (CGs) (Weller et al.
2003; Shimozawa et al. 2004).
At the cellular level, the PBDs can be divided into
defects of peroxisomal membrane biogenesis and matrix
protein import. Three CGs (9, 12, and 14) have blocks
in peroxisome membrane biogenesis and lack identifi-
able peroxisomal structures entirely. The remaining 10
CGs (1, 2, 3, 4, 7, 8, 10, 11, 13, and K [Gifu]) display
defects in peroxisome matrix protein import but retain
the ability to form peroxisomal membranes (Sacksteder
and Gould 2000; Shimozawa et al. 2004). Peroxisomal
matrix proteins are synthesized on free cytosolic ribo-
somes and are targeted posttranslationally to the organ-
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Table 1
Oligonucleotide Sequences
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
elle by cytosolic receptors that bind to cis-acting se-
quences, the peroxisomal targeting signals (PTSs). The
majority of matrix proteins are targeted by the PTS1,
a C-terminal -SKL or conserved variant (Gould et al.
1988, 1989). A few matrix proteins are targeted by a
different sequence, the PTS2, a degenerate sequence—
(R/K)(L/V/I)X5(H/Q)(L/A)—located near the N-termi-
nus (Osumi et al. 1991; Swinkels et al. 1991). PTS1
and PTS2 sequences are recognized by the cytosolic re-
ceptors PEX5 and PEX7, respectively. The receptor/ma-
trix protein complexes assemble in the cytosol and shut-
tle to the peroxisome, where they dock to PEX14, an
integral peroxisomal-membrane protein. Unloading and
translocation of the cargo proteins into the peroxisomal
matrix involves interactions with several other membrane
peroxins (PEX13, PEX10, and PEX12) (Weller et al.
2003). The receptors are recycled back to the cytosol
to participate in another round of import (Dodt and
Gould 1996). Decreased steady-state levels of PEX5 in
cell lines from patients with primary deficiencies of
PEX1 or PEX6 suggest a role for these peroxins in sta-
bilization and/or recycling of the former (Yahraus et al.
1996; Reuber et al. 1997; Collins et al. 2000). PEX1
and PEX6 are AAA ATPases that, in yeast, form het-
erodimeric complexes in an ATP-dependent manner (Fa-
ber et al. 1998a; Birschmann et al. 2005). AAA ATPases
are involved in a diverse set of cellular processes, many
involving protein unfolding, refolding, or the disassem-
bly of protein complexes (Vale 2000; Lupas and Martin
2002). Although the precise roles of PEX1 and PEX6
in the peroxisome membrane protein import process are
unknown, epistasis analyses utilizing the decreased level
of PEX5 in PEX1 and PEX6-deficient cells indicated
that they may act in the disassembly of the multimeric
PEX5-PTS protein complex (preimplex) prior to or dur-
ing the import process (Collins et al. 2000; Gould and
Collins 2002).
Using expression cloning in Chinese hamster ovary
(CHO) cells defective for peroxisome biogenesis, Mat-
sumoto and colleagues (2003a) recently identified PEX26
as the gene responsible for CG8, the last unexplained
human CG. In both human and mouse, PEX26 is a 305-
aa protein with one transmembrane domain, located
near the C-terminus of the protein (aa 252–269) and
an N-terminal domain (NTD) exposed to the cytosol.
Matsumoto and colleagues (2003a) showed that PEX26
binds PEX6 and proposed that it functions to recruit
PEX1 and PEX6 to peroxisomal membranes. Interest-
ingly, they also propose that PEX26 function is required
for import of only catalase and PTS2-targeted proteins
and is not required for import of classical PTS1-targeted
proteins. To date, 12 pathologic PEX26 alleles have been
described in studies of 12 patients with CG8, all with
phenotypes in the Zellweger spectrum (Matsumoto et
al. 2003a, 2003b; Steinberg et al. 2004).
Here, we identify all mutant PEX26 alleles in 10 CG8
probands, including five new PEX26 mutations, and
quantify the peroxisomal import phenotype in CG8 cells
of known genotype, showing that both PTS1- and PTS2-
mediated import is impaired. We also determine the effect
of PEX26 deficiency on PEX5 and PEX1 steady-state
levels and map the PEX6-binding domain in PEX26. Ad-
ditionally, we describe extensive alternative splicing of
PEX26 in fibroblasts and various human tissues that
creates a cytoplasmic, but nevertheless functional,
PEX26 isoform. Extending this observation, we show
that PEX26 mislocalized to the outer mitochondrial
membrane retains its function in peroxisome biogenesis.
Our findings extend the consequences of PEX26 defi-
ciency to PTS1-mediated import and challenge the cur-
rent model of PEX26 function as a docking factor for
the PEX1-PEX6 protein complex at the peroxisomal
membrane.
Material and Methods
PEX26 Amplification and Mutation Detection
We isolated genomic DNA and total RNA from trans-
formed skin fibroblasts with the Puregene and Purescript
kits (Gentra Systems), per the manufacturer’s directions,
and purchased additional human total cellular RNA from
Ambion. We amplified PEX26 exons 1–6 from genomic
DNA (250 ng) and total RNA (0.5–2 mg), using Taq
polymerase (Invitrogen) or the OneStep Cycle kit (Qia-
gen), per the manufacturer’s directions. Oligonucleotide
sequences are shown in table 1 (primers 26-1–26-24).
PCR products were purified from agarose gel (QIAquick
Gel Extraction kit [Qiagen]) and were sequenced directly
by automated fluorescent sequencing. We confirmed each
mutation in amplicons from both genomic DNA and
RNA.
Allele-Specific Oligonucleotide Hybridization (ASO)
We performed ASO analysis to determine the frequency
of missense mutations M1T, L44P, L45P, R98W, and
P117L in exons 2 and 3, as described elsewhere (Ga¨rtner
et al. 1992; Braverman et al. 1997). Sequences of the
wild-type and mutant-specific probes are listed in table
1 (probes 26-25–26-34).
Cell Lines, Transfections, and Immunofluorescence
We analyzed PBD skin fibroblast cell lines assigned to
CG8 by somatic complementation analysis in the collec-
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tion of the Kennedy Krieger Institute, Baltimore. Cell lines
are identified by a unique PBD number assigned to each
proband and are used in all publications from our group.
Cell lines PBD057, PBD111, PBD114, and PBD063
were also studied by Matsumoto and coworkers (2003b)
(in which study they were designated GM11335,
PDL35167, GM08771, and GM16865, respectively).
Cell lines PBD059, PBD063, PBD057, and PBD114
from our study are also available from the Coriell cell
repository (assigned numbers GM17398, GM16865,
GM11335, and GM08771, respectively). Cell lines with
null alleles for PEX1 (PBD009), PEX5 (PBD005), PEX6
(PBD106), and PEX3 (PBD400) have been reported else-
where (Dodt et al. 1995; Yahraus et al. 1996; Reuber et
al. 1997; South et al. 2000). All cell lines were transformed
by transfection with a vector expressing SV40 large T-
antigen, as described elsewhere (Dodt et al. 1995). Ad-
ditionally, cell lines PBD009, PBD005, PBD106, and
PBD400 were immortalized by stable transfection with
a vector that constitutively expresses human telomerase
(pBabePuro/hTER) (Hahn et al. 1999). We cultured the
cells in Dulbecco’s modified Eagle medium high-glucose
supplemented with 10% fetal bovine serum and 100 U
penicillin and 100 mg streptomycin/ml (Gibco). We trans-
fected the cells by electroporation, as described elsewhere
(Chang et al. 1997), and processed the cells for immu-
nofluorescence 48 h later (Warren et al. 1998). We used
monoclonal anti-HA, mono- and polyclonal anti-myc
(BD Bioscience and Santa Cruz Biotechnology), poly-
clonal anti-PEX14 (South et al. 2000), and anti-PMP70
(Shani et al. 1997) as primary antibodies, and we ob-
tained fluorescent secondary antibodies from Vector
Laboratories. Mitochondria were visualized using Mito-
Tracker (Molecular Probes). Microscopy was performed
on a Zeiss LSM510 Meta confocal microscope with the
Carl Zeiss LSM510 Imaging Software.
Plasmids
We constructed the recombinant plasmids to express
full-length human PEX26 cDNA and its splice variants
by cloning RT-PCR amplicons from human control fi-
broblast RNA spanning exons 1–6 (probes 26-15–26-
16) (TOPO TA Cloning [Invitrogen]). After sequence an-
alysis, we transferred the inserts representing full-length
(-FL), exon 5–less (-Dex5) and exon 2–less (-Dex2) PEX26
cDNA into pcDNA3 (Invitrogen), using either the KpnI
and EcoRI restriction sites or the EcoRI restriction
site only (PEX26-Dex2). To produce full-length PEX26
(PEX26-FL) and -Dex5 expression vectors with an N-
terminal myc-tag, we modified the KpnI–Bsu36I frag-
ment, using PCR with a reverse primer incorporating
the myc-sequence (primers 26-39–26-40). To obtain the
myc-tagged PEX26 expression vector lacking exon 5 and
exon 6 (mycPEX26-Dex56), we inserted a stop codon
(c.667GGCrTGA; G223X) following the sequence en-
coded by exon 4 in the cDNA. We PCR amplified a
fragment of mycPEX26-Dex5 with oligonucleotide prim-
ers 26-41 and 26-42, the latter containing the -TGA stop
codon, and cloned the HindIII fragment from this PCR
product into the HindIII sites of mycPEX26-Dex5.
To mislocalize the myc-tagged N-terminus of PEX26
to the outer mitochondrial membrane, we PCR-ampli-
fied the corresponding segment of mycPEX26-FL with
primers that incorporated HindIII and EcoRI restriction
sites (primers 26-51–26-52). Using RT-PCR of rat liver
RNA, we isolated the segment of rat Omp25 cDNA that
encodes the transmembrane segment of the protein
flanked by EcoRI and NotI restriction sites (probes 26-
53–26-54). We ligated these fragments into pcDNA3
(HindIII and NotI) to create a recombinant vector ex-
pressing a chimeric protein, mycPEX26 (aa 2–222)–
OMP25 (aa 170–206) (PEX26-Mito). We used the Quick-
Change XL Site-Directed Mutagenesis Kit (Stratagene),
per the manufacturer’s directions, to introduce L44P
(CTCrCCC) and L45P (CTGrCCG) into PEX26-FL
cDNA expression vector and verified the mutations by
sequencing (primers 26-35–26-38). For N-terminal myc-
tagging of these clones, we used the PCR-modification
strategy of the Kpn I-Bsu36 fragment that is described
above (mycPEX26-L44P and -L45P). pcDNA3 with an
N-terminal 3# HA epitope tag was created by inserting
a PCR product coding for MTSGRIFYPYDVPDYAG
YPYDVPD YA GSYPY-DVPDYALQCGR, flanked by
BglII and XhoI-NotI-XbaI restriction sites into BamHI
and XbaI sites of pcDNA3. To construct a plasmid with
a 3# HA-tag and a 3# nuclear localization signal
(HAnls) for N-terminal tagging of PEX26 fragments, we
inserted a PCR amplicon containing the 3# nls signal
(Jones et al. 1999, 2001) flanked by SalI and XhoI-NotI
restriction sites, as a SalI–NotI fragment into XhoI and
NotI sites of the pcDNA3–3# HA expression vector
(probes 26-55–26-56). Using the new XhoI and the
NotI restriction sites, we inserted PEX26 fragments
obtained by PCR amplification with pcDNA3-PEX26-
FL or PEX26-L44P/L45P as template for expression of
PEX26 peptides corresponding to aa 2–222, aa 2-222-
L44P, aa 2-222-L45P, aa 2–135, aa 2–163, aa 136–222,
and aa 29–174 in frame with the HAnls signal at the N-
terminus (probes 26-43–26-50). PCR-generated PEX26
fragments for expression of peptides corresponding to aa
2–174, aa 2–163, aa 29–174, and aa 69–174 were also
inserted in frame with an N-terminal 3# myc-tag in
pcDNA3 by use of XhoI and NotI restriction sites (Geis-
brecht et al. 1998). pcDNA3-3# HAPEX6 (JM721) and
pcDNA3-3#mycPEX6 (JM709) were constructed by in-
serting the SalI-NotI fragment from pTY3 (Yahraus et
al. 1996) that contained the PEX6 ORF in the XhoI-
NotI sites of the pcDNA3-3# HA (see above) and the
pcDNA3-3# myc expression vector (Geisbrecht et al.
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1998), respectively. The expression vector for pcDNA3-
PEX1 with a C-terminal 3#HA-tag (pBER86) was made
by inserting an ApaI-XhoI fragment that contained three
repeats of the HA epitope tag (see above) between the
ApaI-XhoI sites of pBER81 containing the PEX1 ORF
(Reuber et al. 1997), resulting in an in-frame C-terminal
fusion.
Oligonucleotides used for cloning and mutagenesis
are listed in table 1. We sequenced all recombinant
constructs to verify absence of PCR-introduced muta-
tions. As reporters for peroxisomal-protein import, we
used the following plasmids: pcDNA3-PAHXmyc (Mi-
halik et al. 1997), pcDNA3-NmycPECI (Geisbrecht and
Gould 1999), pcDNA3-NmycHAOX1 (Liu et al. 1999),
pcDNA3-NmycCatalase (Liu et al. 1999), and GFP-SKL.
Characterization of the Cellular Phenotype
and Relative Rescue
We processed cells grown on cover slips for immuno-
fluorescence and counted the numbers of cells expressing
the matrix-protein import markers with variations of the
PTS consensus sequence (see above). We placed each
expressing cell into one of the following categories on
the basis of the distribution of the marker protein: no
import for cytoplasmic-only staining, partial import for
cells with cytoplasmic and peroxisomal staining, and
complete import when the marker protein was exclu-
sively peroxisomal. In a subset of these experiments, the
observer was blind to the cell line and to the transfected
constructs, with results indistinguishable from the non-
blind quantification. Additionally, recounting the same
experiment in a blind fashion gave values differing by
no more than 10%. To calculate percentages of partial
and complete import, we scored at least 500 expressing
cells in each experiment. To determine the comple-
menting activity of PEX26 missense alleles L44P and
L45P and PEX26 splice variants, we calculated the per-
centages of CG8 cells that displayed no import, partial
import, and complete import of mycCAT or GFP-SKL
after cotransfection with nonrecombinant pcDNA3,
PEX26-FL, PEX26-L44P, PEX26-L45P, PEX26-Dex5,
PEX26-Dex2, and PEX26-Mito expression vectors.
Corrected rescue values were calculated by subtracting
the percentage of import observed in cells transfected
with nonrecombinant (empty) vector (typically with a
range of 0%–10% for mycCAT/GFP-SKL in PBD059
cells) from the percentage of import observed in cells
transfected with the PEX26-FL, PEX26 mutant, PEX26
splice variant, and PEX26-Mito expression vectors. Rela-
tive rescue values were obtained by dividing the cor-
rected rescue values by the corrected rescue value de-
termined for the cells transfected with the PEX26-FL
expression vector.
Immunoblot Experiments
We used 15 mg of protein from whole-cell lysates from
the indicated cells, electrophoresed in 7.5% or 10% Tris-
HCl polyacrylamide gels (BioRad), and processed the
gels for immunoblotting, following standard protocols.
Mouse anti-PEX1 monoclonal antibody was purchased
from BD Transduction Laboratories. Rabbit polyclonal
anti-PEX5 antibody was described elsewhere (Dodt et
al. 1995). Rabbit polyclonal anti-PEX13 antibody is
directed against a C-terminal PEX13 peptide (South et
al. 2000). We used anti-tubulin (Sigma) as a loading
control. All results were obtained in duplicate in two
experiments.
Antibodies directed against PEX26 were generated by
immunization of rabbits with an N-terminal PEX26 pep-
tide (NH2-MKSDSSTSAAPLRGLC-COOH) conjugated
to keyhole limpet hemocyanin as a carrier protein (Co-
vance Research Products). In vitro transcription and
translation of full-length PEX26 was performed with the
TnT T7 Coupled Reticulocyte Lysate System (Promega),
per the manufacturer’s directions.
Results
PEX26 Full-Length Transcripts and Orthologs
PEX26 maps to 16.9 Mb at 22q11.21, just centrom-
eric of the region typically deleted in DiGeorge/velocar-
diofacial syndrome (McDermid and Morrow 2002), and
has seven predicted exons distributed over 13 kb, with
the translation start site located in exon 2. In our RT-
PCR experiments, we routinely use a primer (26-15)
corresponding to the 5′ end of exon 1, as predicted by
the PEX26 cDNA with GenBank accession number
NM_017929.
Using the human PEX26 amino acid sequence as a
probe to screen public databases, we detected multiple
vertebrate orthologs (Mus musculus, Rattus norvegicus,
Gallus gallus, Danio rerio, Fugu rubripes, Tetraodon ni-
griviridis) but none in invertebrates. In D. rerio and T.
nigriviridis, PEX26 orthologs show 30% and 32%, re-
spectively, sequence identity with human PEX26 (fig. 1).
Saccharomyces cerevisiae PEX15 resembles vertebrate
PEX26 in topology (both are type II integral membrane
proteins) and in binding of PEX6, but we found no de-
tectable amino acid sequence similarity (12% overall iden-
tity between S. cerevisiae PEX15 and human PEX26, with
no blocks of identical amino acids 12 residues).
PEX26 Mutation Analysis
Using RT-PCR of patient fibroblast RNA with confir-
mation by amplification of the indicated exons in genomic
DNA, we found nine PEX26 alleles that accounted for
all 20 mutant PEX26 genes in 10 CG8 probands (table
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Figure 1 Sequence comparison of vertebrate PEX26 orthologs. Alignment of human (Hs), mouse (Mm), T. nigroviridis (Tn), and D. rerio
(Dr) PEX26 amino acid sequence. HsPEX26 is 73%, 32%, and 31% identical to mouse, T. nigriviridis, and D. rerio PEX26, respectively. Amino
acids identical across all four species are highlighted in black; those with a plurality are in gray. The positions of PEX26 missense mutations
identified in this study are indicated. The solid line marks the segment of human PEX26 encoded by the alternatively spliced exon 5; the dashed
line indicates the predicted transmembrane domain.
2). Of these alleles, five are newly recognized (Matsumoto
et al. 2003a, 2003b; Steinberg et al. 2004). One proband
with a ZS phenotype (PBD059) is homozygous for a mu-
tation in the splice-donor site of intron 2, c.2301GrT,
which leads to a frameshift at T77 and premature termi-
nation (T77fs139X) (see table 2). Four patients with an
NALD or IRD phenotype (PBD111, PBD057, PBD161,
and PBD065) are homozygous for a transition in exon 3,
c.292CrT, which results in the previously reported mis-
sense mutation R98W. PBD063, with a ZS phenotype, is
a compound heterozygote for R98W and an insertion of
thymidine at position 254 in the cDNA (c.254insT; exon
3), which results in a frameshift and premature termi-
nation (C86fs114X). In PBD055, with an IRD pheno-
type, we detected three heterozygous mutations. In exon
3, a c.350CrT transition results in P117L; in exon 4,
c.457CrG results in L153V; and, in exon 6, a single
base-pair deletion (c.862delC) causes a frameshift at
R288 with termination 79 aa downstream (R288fs366X).
L153V is in cis with R288fs and is a known SNP
(rs12484657). PBD110 is a compound heterozygote for
L44P and R98W. PBD114 is a compound heterozygote
for M1T and L45P. The first methionine downstream
from M1 is M96, which is embedded in an acceptable
Kozak consensus sequence (GCAGAAAUGG, com-
pared with the consensus GCCPuCCAUGG), which
suggests that translation could initiate at this position
(Kozak and Harper 2000). PBD109 is a compound het-
erozygote for R98W and a complicated allele with a
122-bp duplication separated by an inserted thymidine
(c.426_548dup122bpinsT) that maintains frame and
predicts a protein in which aa 134–182 are tandemly
duplicated, with substitution of glycine by valine at po-
sition 183 (A134_V182dupG183V).
Functional Consequence of PEX26 Missense Alleles
L44P and L45P
Of these nine PEX26 alleles, four (M1T, L45P, R98W,
and c.254insT) were shown elsewhere to be functionally
significant by expression in a PEX26-deficient CHO cell
line (Matsumoto et al. 2003b). We assumed functional
significance for three nonsense or frameshift mutations
that disrupted a large segment of PEX26 (c.2301GrT,
L153VR288fs, and A143_V182dupG183C). To test
the functional consequences of PEX26-L44P and -L45P,
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we expressed them in transformed fibroblasts from a CG8
patient (PBD059) who was homozygous for a PEX26
null allele, and we compared their ability to restore ma-
trix-protein import with wild-type PEX26 (relative res-
cue). In two separate experiments, PEX26-L44P had 1%
and 8% relative-rescue activity, whereas PEX26-L45P
had 0% relative-rescue activity in both trials. Thus, both
these mutants severely reduce the function of PEX26.
Frequency of Mutant Alleles
To estimate the frequency of the five missense alleles
(M1T, L44P, L45P, R98W, and P117L) in the general
population, we amplified PEX26 exons 2 and 3 from
genomic DNA of 53 individuals of mixed ethnicity, and
we genotyped them by allele-specific oligonucleotide hy-
bridization. We detected none of the mutations in these
106 control chromosomes and conclude all are relatively
rare variants.
Cellular Phenotype of PEX26-Deficient Fibroblasts
A previous study concluded that PTS1 import is nor-
mal in PEX26-deficient cells, a result that is surprising,
given that the clinical phenotype of the patients is in the
Zellweger spectrum rather than RCDP (Matsumoto et
al. 2003b). To determine the extent and severity of the
import defect for peroxisomal matrix enzymes in PEX26-
deficient fibroblasts from individuals with known geno-
type, we made use of the differing import efficiency as-
sociated with variation in the PTS1 (Liu et al. 1999).
We determined the matrix-protein import of a series of
PTS1-targeted proteins ranging from the canonical
-SKL targeted peroxisomal D3, D2 enoyl-CoA isomerase
(PECI) (Geisbrecht and Gould 1999); the near-consensus
-SKI targeted human peroxisomal glycolate peroxidase
(HAOX1) (Jones et al. 2000); and the most atypical
PTS1, -KANL, found in catalase (CAT) (Lazarow et al.
1982; Bell et al. 1986; Purdue and Lazarow 1996). We
also tested PTS2 import by analyzing the distribution of
phytanoyl-CoA hydroxylase (PAHX) (Mihalik et al.
1997). We compared the peroxisomal matrix import of
these reporters in transformed fibroblasts of patients
PBD059, PBD111, PBD057, PBD110, and PBD114 to
that in cells from PEX1-, PEX5-, and PEX6-deficient
patients and a control individual. As predicted by the
degree of conservation of the PTS1, import for these
markers varied with (fig. 2). ThePECI 1 HAOX1 1 CAT
cells of all PEX26-deficient patients had some residual
import in this assay. PBD059, with a ZS phenotype
(c.2301GrT/c.2301GrT), showed the most severe
impairment, with residual import of mycPECI only. In
contrast, cells from two R98W homozygotes (PBD111
and PBD057), both with an NALD phenotype, displayed
the mildest import phenotype, with residual import for
all marker proteins. Fibroblasts of PBD110 (L44P/R98W
[NALD]) and PBD114 (M1T/L45P [IRD]) had minimal
residual import for most marker proteins tested. Thus,
there is a limited correlation between the cellular phe-
notype as measured in this assay and the clinical phe-
notype in these patients. Interestingly, cells from patients
with null mutations in PEX1, PEX6, and PEX5 all had
a more severe import phenotype than we observed in
any of the PEX26-deficient cells, including the presumed
null, PBD059, which had some residual import of the
reporter with the most conserved PTS1 signal (PECI;
24% residual import). Our results differ from those of
Matsumoto and coworkers, who interpreted their immu-
nofluorescence data with an antibody directed against
the canonical PTS1 (-SKL) as showing normal import
of PTS1-targeted matrix proteins (Matsumoto et al.
2003a, 2003b). Our results showing a generalized defect
in PTS1-mediated import are consistent with the Zell-
weger spectrum clinical phenotype of the patients with
CG8.
PEX26, PEX5, and PEX1 Steady-State Levels
in PEX26-Deficient Fibroblasts
Immunoblot studies with anti-PEX26 antibody iden-
tified a protein of the size predicted for PEX26 (34 kD)
in lysates of wild-type but not PBD059 cells. The anti-
body also detected a 34-kD protein produced in in vitro
transcription and translation of a full-length PEX26
cDNA. Preincubation of the antibody with the specific
but not with a nonspecific peptide blocked binding to
the 34-kD protein (fig. 3). We conclude that our anti-
body specifically detects PEX26. A larger, cross-reacting
protein is present in the immunoblots of wild-type and
CG8 samples and is detected with either preimmune or
immune serum (fig. 3).
Immunoblots of lysates of all CG8 cell lines tested
showed no detectable PEX26, which indicates that the
PEX26 mutations in these cell lines destabilize the pro-
tein product. Previous studies of monogenic defects in
peroxisome biogenesis have shown that a primary defect
in one component of the matrix-protein–import appa-
ratus may result in a secondary deficiency of other com-
ponents. For example, primary defects in PEX1 or PEX6
result in a marked secondary deficiency of PEX5 (Dodt
and Gould 1996; Collins et al. 2000). Similarly, we found
that, compared with wild type, PEX26 was reduced but
detectable in lysates of reference PEX1-, PEX5-, and
PEX6-deficient cell lines. In at least six CGs, including
those caused by deficiency of PEX1, -5, and -6 (CG1,
CG2, and CG4, respectively), peroxisomes are enlarged
but show a 5-fold decrease in abundance (Chang et al.
1999). To exclude the possibility that the observed re-
duction in PEX26 level was secondary to a reduction of
peroxisomal membrane, we examined the level of PEX13,
an integral peroxisomal membrane protein, in this same
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Figure 2 Cellular phenotype of cultured skin fibroblasts from PEX26-deficient patients. A–C, Example of merged images of transfected
human fibroblasts showing complete (A), partial (B), or no (C) peroxisomal import of the indicated reporter. Indirect immunofluorescence
staining of peroxisomal membranes was with anti-PEX14 antibody (Texas Red), and staining of a reporter peroxisomal matrix protein was
with anti-myc antibody (FITC). Yellow indicates colocalization of the peroxisomal marker and the matrix-protein marker. D, Percentage of
transfected cells displaying complete and partial import of the indicated matrix proteins. The vertical bars indicate the total percentage of cells
showing import. The light horizontal line dividing each vertical bar indicates the fraction of cells scored as partial import (below the line) and
complete import (above the line). The values represent the means of two experiments, except for (1) wild type, PBD059 and PBD111 transfected
with mycPECI, and mycCAT (three experiments); and (2) PBD057 transfected with mycPECI, mycHAOX1, and PAHXmyc and PBD114
transfected with mycHAOX1, mycCAT, and PAHXmyc (one experiment); the value for PBD114 with mycPECI was not determined.
set of cell lines. The levels of PEX13 were essentially the
same as in control cells (fig. 3). Thus, the decrease in
PEX26 seems to be a specific consequence of deficiency
of PEX1, PEX5, or PEX6.
To determine if PEX26 deficiency affects the steady-
state level of PEX5 or PEX1, we used total protein from
whole-cell lysates from selected CG8-, CG1-, CG2-, and
CG4-transformed fibroblasts for immunoblot experi-
ments (fig. 3). As expected, we found no effect of PEX26,
PEX5, or PEX6 deficiency on PEX1 levels. Unfortu-
nately, neither we nor others have been able to develop
an antibody to assess PEX6 levels. PEX5 levels were
equally reduced in all CG8 cell lines and in PEX1- and
PEX6-deficient cells.
Alternative Splicing of PEX26
During the course of our RT-PCR experiments with
fibroblast RNA, we detected three shorter amplified
products in addition to the expected full-length product
of 1,508 bp (PEX26-FL) (fig. 4). We cloned and se-
quenced these shorter cDNAs and found that they rep-
resented splice variants of PEX26. We found a similar
pattern of these PEX26 splice forms in RNA from sev-
Figure 3 Immunoblot analysis of PEX26 and related peroxins in PBD fibroblasts. All panels show fibroblast lysates (15 mg/lane) or the
products of in vitro transcribed and translated full-length PEX26 (PEX26T/T) electrophoresed in 7.5% or 10% polyacrylamide gels, under
denaturing conditions, transferred to nylon filters, and detected with the indicated antibody or antiserum. Panels A and B show characterization
of our anti-PEX26 N-terminal peptide (NH2-MKSDSSTSAAPLRGLC-COOH) antibody. A, Blots of lysates from control fibroblasts, a PEX26-
deficient cell (PBD059, c.2301GrT/c.2301GrT), and PEX26T/T detected either with anti-PEX26 (top) or preimmune serum (bottom). The
filled wedge () indicates PEX26 (34 kDa), detected only in control fibroblasts and in the PEX26T/T products; the dots indicate nonspecific
background bands present in fibroblast lysates; the unfilled wedge (1) indicates the expected location of PEX26 in the preimmune panel. B,
Lysates from the indicated sources stained with anti-PEX26 antibody preincubated with either a nonspecific (unrelated) peptide (NH2-
QKQEHSGSEEAQKPNC-COOH) (top) or with the specific N-terminal PEX26 peptide used as immunogen (NH2 -MKSDSSTSAAPLRGLC-
COOH) (bottom). The lysate designated PBD059PEX26 is from PEX26-null cells transfected with full-length PEX26. The filled wedge ()
indicates PEX26 (top); the unfilled wedge (1) indicates expected location of PEX26 (bottom). Note that preincubation with the specific immunizing
peptide but not with the unrelated nonspecific peptide completely blocks detection of PEX26. C, Immunoblots of lysates from cells of the
indicated genotype stained with anti-PEX26 antiserum and anti-tubulin as a loading control (top panel). The second panel shows the same
lysates stained with anti-PEX13 as a measure of the amount of peroxisome membrane in each sample, also with anti-tubulin as a loading
control. The third panel shows the same lysate stained with anti-PEX5 and the bottom panel with anti-PEX1. In all panels, the PEX26 genotype
is indicated above. The identity and genotypes of the cell lines with mutations in other PEX genes are as follows: PEX1/, PBD009 (c.2097insT/
IVS181GrA) (Reuber et al. 1997); PEX5/, PBD005 (R390X/R390X) (Dodt et al. 1995); and PEX6/, PBD106 (c.del23982417insT/
c.19621GrA).
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Figure 4 PEX26, alternatively spliced in fibroblasts and human tissues. Top panel, The products of RT-PCR amplification of PEX26
transcripts. RT-PCR products with total RNA from human liver, kidney, heart, and brain, by use of primers complementary to the 5′ and 3′
ends of full-length PEX26 transcript (probes 26-15 and 26-16, respectively), analyzed by agarose-gel electrophoresis and ethidium-bromide
staining. The source of the RNA is indicated above the five lanes on the left. On the right, we cloned the RT-PCR products (1,508, 1,361,
1,197, and 1,065 bps) from fibroblast RNA, and the inserts representing full-length PEX26 cDNA (A), PEX26-Dex5 (B),PEX26-Dex2 (C), and
PEX26-Dex45 (D) splice forms are shown as size references. Lower panel, Full-length PEX26 transcript, except for exon 7, which encodes
3′ untranslated sequence and is not included in the RT-PCR amplicons. The segments contributed by each exon are numbered and shown to
scale. The flag shows the translation start site, the cross-hatched rectangle indicates the segment of exon 5 encoding the transmembrane domain,
and the asterisk (*) indicates the translation stop site. The letters indicate the exon deleted from the similarly lettered splice form shown in the
top panel.
eral tissues in relatively similar ratios (fig. 4). As com-
pared with PEX26-FL, the next smaller product (1,361
bp) lacks exon 5 (PEX26-Dex5). The ORF of this splice
form maintains frame and encodes a protein that is 49
aa shorter than full-length PEX26, lacking the 18-aa
transmembrane domain of full-length PEX26 (fig. 4).
The next shorter splice form (1,197 bp) results from
skipping of exon 2 (PEX26-Dex2). Exon 2 encodes the
N-terminus of PEX26, so this splice form would encode
an N-terminal–truncated protein initiating at the next
downstream methionine (M96). The next shorter splice
form is 1,065 bp and lacks exons 4 and 5 (PEX26-
Dex45). This splice form encodes a protein with the
124 N-terminal amino acids of PEX26, followed by a
frameshift with an intact ORF, for 32 additional codons.
In one RT-PCR experiment with heart mRNA, we also
detected a faintly staining product that was 248 bp
longer than PEX26-FL (data not shown). Cloning and
sequencing revealed that intron 1 (248 bp) was retained
in this product. Since the translation initiation site is
located in exon 2, the complete ORF of PEX26-FL is
intact in this splice form. A BLASTN search against the
human EST database with use of PEX26 exon 1 plus
exon 2 as a probe identified 19 ESTs containing exon 1
and exon 2 sequences. Intron 1 was retained in nine. In
BLASTN searches with PEX26 cDNA exons 1–6, we
found eight ESTs that contain or span the segment con-
tributed by exon 5. Of these, two were the PEX26-Dex5
splice variant. We did not find a PEX26 EST corre-
sponding to PEX26-Dex2.
Complementing Activity and Subcellular Localization
of PEX26 Isoforms
To examine the functional significance of the two splice
variants that retain frame (PEX26-Dex5 and PEX26-
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Dex2), we expressed them in control fibroblasts and in
PEX26-deficient fibroblasts with various PEX26 geno-
types (PBD059, PBD111, PBD057, and PBD110). In
control cells, neither PEX26 splice form had an effect
on matrix-protein import (data not shown), nor did
PEX26-Dex2 rescue-matrix–protein import in any of the
PEX26-deficient cell lines. By contrast, the relative-res-
cue activity of PEX26-Dex5 was the same as PEX26-
FL (fig. 5). This result was surprising, given that PEX26-
Dex5 lacks the predicted transmembrane domain of
PEX26, expected to be essential for its putative function
as a docking protein for PEX1 and PEX6 (Matsumoto
et al. 2003b).
To determine the subcellular localization of the com-
plementing PEX26 isoforms, we added N-terminal myc-
tags to PEX26-FL and PEX26-Dex5. We also produced
a myc-tagged PEX26 expression vector that lacked exon
5 and exon 6 (mycPEX26-Dex56, encoding PEX26
(aa 2–222). The relative-rescue activities for GFP-SKL
import of mycPEX26-Dex5 and mycPEX26-Dex56,
as compared with mycPEX26-FL, were 84%/77% and
65%/34% for PBD059/PBD110 cell lines. Thus, addi-
tion of the N-terminal myc-tag did not have a deleterious
effect on the function of the PEX26 isoforms and, con-
sistent with our results with PEX26-Dex5, PEX26-
Dex56 encodes a partially functional protein. The sub-
cellular localization of these various PEX26 isoforms is
shown in figure 6. mycPEX26-FL is completely localized
to peroxisomes, as indicated by a punctate staining pat-
tern that colocalizes with PMP70. By contrast, the lo-
calization of mycPEX26-Dex5 and mycPEX26-Dex56
was similar and clearly different from that of mycPEX26-
FL. Both show substantial localization to the cytosol,
with some localization to the ER for mycPEX26-Dex5.
These results suggest that a peroxisomal membrane lo-
cation is not required for PEX26 function.
Mapping of PEX6 Binding in PEX26
Using Co-IP with epitope-tagged proteins and GST–
pull down experiments, Matsumoto and colleagues
(2003b) showed binding between full-length PEX26
and PEX6. We asked which part of PEX26 is essential
for this interaction. To provide a discrete, easy-to-score
subcellular location for these binding experiments, we
mislocalized PEX26 fragments to the nucleus (HAnls-
PEX26) (Sacksteder et al. 2000) in transformed fibro-
blasts from a PEX3-deficient patient (PBD400). These
cells lack peroxisomes, as detected with antibodies to
either peroxisome matrix or membrane proteins (South
et al. 2000). We cotransfected PBD400 cells with
myc-tagged PEX6 and either pcDNA3 or recombinant
pcDNA3 carrying HAnls-PEX26 fragments (fig. 6).
mycPEX6 was evenly distributed in the cytosol and was
barely detectable in the nucleus when cotransfected with
pcDNA3 vector alone. Cotransfection with HAnls-
PEX26 (aa 2–222), which includes ∼90% of the cyto-
plasmic domain of PEX26, altered mycPEX6 localiza-
tion to the nucleus. Using serial N- or C-terminal de-
letions of HAnls-PEX26, we identified aa 29–174 as a
minimal fragment sufficient to localize mycPEX6 to the
nucleus. HAnls-PEX26 (aa 2–163) had a variable effect
on mycPEX6 localization, whereas two overlapping frag-
ments, HAnls-PEX26 (aa 2–135) and HAnls-PEX26 (aa
136–222), showed no binding of mycPEX6. These re-
sults indicate that the segment of PEX26 required for
interaction with PEX6 includes aa 29–163. Moreover,
we found that HAnls-PEX26 (aa 2–222) with either the
L44P or the L45P mutations produced a stable protein
that did not direct mycPEX6 to the nucleus, which sug-
gests that these mutations interfere with the binding of
PEX6 to PEX26.
In line with these results, expression of full-length
PEX26-L44P and PEX26-L45P does not result in the
localization of mycPEX6 to peroxisomes that is observed
with expression of wild-type PEX26-FL. We repeated
this experiment with myc-tagged wild-type and mu-
tant PEX26-FL (mycPEX26-FL, mycPEX26-L44P, and
mycPEX26-L45P) and found that wild-type and mutant
mycPEX26-FL are stable and localized on peroxiso-
mal membranes, but only the wild-type protein directs
HAPEX6 to peroxisomes (data not shown).
PEX26-Deletion Mutants and the Minimal
Complementing Fragment
To determine whether the function of PEX26 neces-
sary for peroxisome biogenesis can also be mapped to
a smaller segment in the NTD, we constructed a series
of deletion mutants with an N-terminal 3# myc-tag. We
verified the expression of the deletion mutants in the
cytosol of PBD059 cells, with indirect immunofluoresc-
ence staining against the myc-tag. The smallest fragment
able to complement PBD059 cells comprised aa 2–174
(53% and 56% relative rescue of GFP-SKL import over
PEX26-FL in two trials). PEX26 fragments comprising
aa 2–163 or less had no complementing activity. Using
N-terminal deletions, we found that a peptide compris-
ing aa 29–174 retained 36% relative-rescue activity,
whereas fragments with aa 69–174 or smaller did not
complement PBD059 cells (data not shown). Thus, the
functional domain of PEX26 corresponds to aa 29–
174—or nearly exactly to the PEX6-binding domain.
Expression of PEX26 on the Outer Mitochondrial
Membrane
The results of our binding and splicing studies show
that PEX26 does not require a peroxisomal location to
rescue-matrix–protein import. To further test the func-
tion of extraperoxisomal PEX26, we elected to localize
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Figure 6 PEX26 segments aa 29–174 and 2–163, sufficient for PEX6 binding, as detected in a nuclear mislocalization assay. We transfected
fibroblasts lacking peroxisomes due to an inherited deficiency of PEX3 (PBD400) with pcDNA3–3# mycPEX6 and either nonrecombinant
pcDNA3 vector alone or recombinant pcDNA3 expressing N-terminal HA-tagged, nls-PEX26 fragments comprising the indicated segments of
PEX26, and we analyzed them by indirect immunofluorescence with anti-HA (Texas Red), anti-myc (FITC) antibodies, and DAPI counterstaining,
to show nuclei. The bottom two rows show expression of PEX26 segments sufficient to bind PEX6 but with the indicated missense mutations.
it to a discrete and remote site, the outer mitochondrial
membrane. To do this, we expressed a chimeric protein
consisting of an N-terminus of Nmyc-tagged PEX26 (aa
2–222) and a C-terminus of rat OMP25 (aa 170–206)
(PEX26-Mito) in PBD059 cells. Targeting to the mito-
chondrial outer membrane with an Nout-Cin orientation
for N-terminal chimeric proteins, with use of this frag-
ment of rat OMP25, has been described elsewhere (Horie
et al. 2002). We found that PEX26-Mito is localized
exclusively on mitochondria (fig. 7), which is consistent
with these earlier studies. Surprisingly, despite this ec-
topic location, expression of PEX26-Mito in PBD059
cells resulted in complete restoration of peroxisome ma-
trix-protein import. Relative-rescue activity of PEX26-
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Mito compared with PEX26-FL was 180% and was even
better than that of cytosolic mycPEX26-Dex56 (aa 2–
222) in these experiments (63%–66%) (fig. 7).
Localization of PEX6 and PEX1 in PEX26-Deficient
Cells Expressing Functional PEX26-Mito
Previous work showed that PEX26 binds PEX6 di-
rectly and PEX1 indirectly through the PEX6 interaction
(Matsumoto et al. 2003b). Our data show that locali-
zation to peroxisomes is not essential for PEX26 func-
tion and that the minimal PEX26 fragment necessary to
complement CG8 cells retains the ability to bind PEX6.
To understand how PEX26 functions in an extraperoxi-
somal location, we determined the localization of PEX6
and PEX1 in PBD059 cells complemented with PEX26-
Mito (fig. 8). Colocalization of these AAA ATPases with
PEX26-Mito would support the hypothesis that PEX26-
PEX6-PEX1 interaction is essential for peroxisome ma-
trix-protein import but would be surprising, because
current models predict that the PEX1-PEX6 hetero-olig-
omer acts at the peroxisomal membrane; for example,
in the disassembly of PEX5-PTS1 and PEX7-PTS2 com-
plexes just prior to translocation of PTS1 and PTS2 pro-
teins into the organelle (Gould and Collins 2002). In
PBD059 cells cotransfected with empty vector and 3#
HA-tagged PEX6 (JM721), we found that PEX6 local-
izes to the cytosol and does not accumulate on the mem-
branes of either peroxisomes or mitochondria (fig. 8, A
and B). Addition of PEX26-Mito results in a dramatic
change, with complete colocalization of PEX6 with
PEX26-Mito on the mitochondria (fig. 8, C and D).
Under these conditions, we detected no colocalization
of PEX6 with PMP70 on peroxisomal membranes (fig.
8, E).
Interestingly, PBD059 cells transfected with PEX1-
3# HA (pBER86)—untagged PEX6 and empty vector—
show a bimodal distribution of PEX1, with most in the
cytosol but some on peroxisomal membranes, as marked
by PMP70 (fig. 8, F). This result suggests that a fraction
of PEX1 localizes to the peroxisome membrane despite
the lack of detectable PEX26 and PEX6 in this location.
Addition of PEX26-Mito dramatically alters the locali-
zation of PEX1, with most now colocalizing with PEX26-
Mito on the mitochondrial outer membrane (fig. 8, H
and I). Interestingly, in contrast to PEX6, a fraction of
PEX1 retains a residual peroxisomal localization in cells
cotransfected with PEX26-Mito (fig. 8, J).
We tested 3# HA-PEX6 and PEX1-3# HA for their
ability to complement PEX6- and PEX1-deficient cell
lines, respectively. In two independent experiments, they
maintained 52%–62% and 61%–77% relative-rescue
activity, respectively, compared with the untagged pro-
teins for import of GFP-SKL (data not shown). The lo-
calization of 3# HA-PEX6 and PEX1-3#HA with and
without cotransfection of PEX26-Mito was confirmed
in at least three independent experiments. Although the
amount varied, we found some PEX1 on peroxisomes
in all cotransfection experiments with PEX26-Mito, un-
tagged PEX6, and tagged PEX1. Panel J of figure 8 shows
a cell with a typical ratio of peroxisomal to mitochon-
drial location of PEX1.
These results suggest that peroxisomal localization of
neither PEX26 nor PEX6 is essential for peroxisome
matrix-protein import. By contrast, we detected some
PEX1 on peroxisomal membranes in cotransfection ex-
periments with PEX26-Mito and PEX6. Thus, a per-
oxisomal location of some fraction of PEX1 may be
required for matrix-protein import. The observations
raise the question of how the interaction of PEX26-
PEX6—and possibly of PEX1—at an extraperoxisomal
localization participates in peroxisome matrix-protein
import.
Discussion
The recent identification of PEX26 by Matsumoto and
colleagues completed the search for the genes responsible
for the 12 recognized CGs for the Zellweger spectrum
subgroup of the PBDs (Matsumoto et al. 2003a, 2003b)
These investigators showed that PEX26 encodes a 305-
aa, 34-kD integral peroxisomal membrane protein with
a single C-terminal transmembrane domain near the C-
terminus, a short (∼36 aa) intraperoxisomal C-terminal
tail, and long (250 aa) N-terminus exposed to the cy-
tosol. They also showed that PEX26 binds PEX6 directly
and PEX1 indirectly, through the interaction with PEX6.
The latter are AAA ATPases that have been proposed
to act late in the peroxisomal matrix-protein import cy-
cle (Collins et al. 2000; Vale 2000). Together, mutations
in PEX1, PEX6, and PEX26 account for a large fraction
(∼70%) of all patients with PBD (Gould and Valle 2000).
In this work, we have identified 5 new PEX26 mutant
alleles, which brings the total to 17. Of these, six are
missense mutations in the N-terminal, cytosolic 60% of
the protein, a segment with greater sequence identity
across the recognized PEX26 vertebrate orthologs, as
compared with the remaining C-terminal segment (e.g.,
human compared with Danio has 38% identity vs. 24%
identity, respectively) (fig. 1). We find that none of these
missense mutations are common in the general popu-
lation, although R98W accounts for 14 (39%) of the
mutant PEX26 genes in the total collection of 18 ge-
notyped probands with CG8 (10 patients in our study
and 7 in that of Matsumoto et al., with four overlaps,
and 5 in that of Steinberg et al.). The high frequency of
R98W may represent a founder effect, as has been de-
scribed for certain alleles in other PBD CGs (Braverman
et al. 1997), or recurrent mutations at a CpG dinucleo-
tide in codon 98 (CGGrTGG). Haplotype studies will
be necessary to distinguish between these possibilities.
In patient fibroblasts expressing endogenous PEX26,
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our immunoblot studies indicate that all of the missense
mutations we tested are associated with a substantial
reduction in steady-state levels of PEX26 (fig. 3). Thus,
the major pathological consequence of these mutations
in vivo appears to be destabilization of PEX26, a result
that is similar to the consequences of disease-associated
missense mutations at other loci (Brody et al. 1992).
Additionally, our immunoblot studies suggest that cells
with null mutations in PEX1 or PEX6 also appear to
have some reduction in PEX26 that is not simply ex-
plained by alterations in the amount of peroxisomal
membrane, as indicated by the similar levels of the in-
tegral peroxisome membrane protein PEX13 in all sam-
ples (fig. 3). The explanation for this observation is
uncertain, but the finding is consistent with a model in
which PEX26, PEX1, and PEX6 interact in a functional
unit (see below).
As an additional aspect of the cellular phenotype, we
also examined the steady-state levels of the PTS1 re-
ceptor PEX5 in the PEX26-deficient cells (fig. 3). Re-
duced abundance of PEX5 is characteristic of PEX1- and
PEX6-deficient cell lines and has been reported else-
where in a PEX26-deficient cell line (Dodt and Gould
1996) but is not observed in human cells with primary
defects in PEX2, PEX7, PEX10, PEX12, or PEX16
(Dodt and Gould 1996; Yahraus et al. 1996; Sacksteder
and Gould 2000). Reduced PEX5 steady-state levels are
also found in yeast cells with primary defects in Pex1
and Pex6 (Collins et al. 2000). In our studies, we found
a severe reduction in PEX5 in five different PEX26-
deficient cell lines, independent of their genotype and
similar in extent to that we observed in PEX1- and
PEX6-deficient cells (fig. 3). This result also is consistent
with a model in which PEX26, -1, and -6 work together
as a functional unit whose activity influences the levels
of PEX5. The levels of PEX1, by contrast, in the same
set of cell lines, are normal or nearly so, and we are
unable to measure PEX6 levels because of lack of an
appropriate antibody.
Curiously, Matsumoto et al.—using indirect immuno-
fluorescence staining for endogenous PTS1-targeted ma-
trix proteins (detected with an anti-peptide antibody
directly against the consensus PTS1, -SKL), catalase
(targeted by an atypical PTS1, -KANL), and peroxiso-
mal thiolase (a PTS2-targeted protein)—concluded that
the cellular phenotype of PEX26-deficient cells was
characterized by impaired peroxisomal import of cata-
lase and PTS2-targeted proteins with normal import of
classical PTS1-targeted proteins. Given that the clinical
phenotype of primary deficiency of catalase involves ei-
ther adult-onset oral ulcers or no symptoms at all (Wan-
ders et al. 2001), this conclusion suggests that the
clinical phenotype of PEX26-deficient patients would
mainly reflect deficiency of PTS2-targeted proteins and,
therefore, should resemble RCDP (caused by deficiency
of the PTS2 receptor, PEX7) rather than the Zellweger
spectrum, as described for patients with CG8 (see table
2). To address this discrepancy, we performed quanti-
tative studies of the peroxisomal import of a set of four
matrix proteins targeted by consensus (-SKL, PECI),
near consensus (-SKI, HAOX1), or atypical (-KANL,
catalase) PTS1-targeting signals plus a consensus PTS2-
targeted protein, PAHX, in four CG8 cell lines with a
variety of PEX26 genotypes. Although there is some
residual import, our results show a clear and substantial
defect in all three PTS1-targeted reporters, most severe
for catalase but substantial for PECI and HAOX1 (14%–
77% of control and 0%–30% of control, respectively,
depending on cell line) (fig. 2). These results are con-
sistent with the Zellweger spectrum clinical phenotype
of PEX26-deficient patients and with a model of PEX26
function that involves interaction with PEX6 and PEX1,
both of which are known to be necessary for the import
of PTS1-targeted proteins. The reason(s) for the dis-
crepancy between our results and those of Matsumoto
et al. is unclear. It is possible that by using an antibody
expected to detect any matrix protein with a classic
(-SKL) PTS1-targeting signal, some or all of which may
have a low level of residual import in PEX26-deficient
cell lines, Matsumoto et al. may have underestimated
the effect of PEX26 mutations on PTS-1–mediated im-
port. Our studies also show a rough correlation of
PEX26 genotype with cellular phenotype. The predicted
null PBD059 (c.2301GrT/c.2301 GrT genotype)
cells show the most severe defect in matrix-protein im-
port and two cell lines homozygous for R98W showing
the mildest defect, with some residual import for all
four reporters. Moreover, there is a suggestion of cor-
relation of genotype with clinical phenotype. PBD059
had ZS, the most severe clinical phenotype, whereas
seven probands either homozygous or heterozygous for
R98W had milder phenotypes, ranging from NALD to
IRD (table 2).
At the mRNA level, we observed extensive alternative
splicing of PEX26 transcripts in RNA isolated from fi-
broblasts and in multiple human tissues (fig. 4). The
most informative of these alternatively spliced tran-
scripts skips exon 5 and encodes a PEX26 isoform of
256 aa that lacks the transmembrane domain of the
full-length protein (fig. 1). If, as previously suggested,
the function of PEX26 is to recruit the PEX1/PEX6
heterodimer to peroxisomes, this splice form seemed
likely to encode a functionally inactive form of PEX26.
Surprisingly, our expression studies showed this isoform
is functionally active despite being located in the cytosol
(fig. 5). This result shows that a peroxisomal location
is not required for PEX26 function and that the essential
function(s) of PEX26 in peroxisome biogenesis involves
more than recruitment of PEX6 to the organelle (see
below).
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Although we find no sequence similarity between ver-
tebrate PEX26 and S. cerevisiae Pex15 (see above), they
share a type II membrane protein topology, and both
have been described as a PEX1/PEX6 anchoring site at
the peroxisomal membrane (Birschmann et al. 2003;
Matsumoto et al. 2003a). In an attempt to establish ad-
ditional functional similarities between human PEX26
and S. cerevisiae Pex15, we asked if a cytosolic form of
Pex15 is functional in peroxisome biogenesis. We tested
two TMD-less constructs of PEX15 (aa 2–330 and aa
2–260). In contrast to our results with PEX26 in human
cells and with full-length PEX15 (aa 2–283) in S. cer-
evisiae, we found that the transmembrane domain–less,
cytosolic form of Pex15 did not rescue peroxisome ma-
trix-protein import in a Dpex15 yeast strain (I.C., S.W.,
S.J.G, and D.V., unpublished results).
Estimating from our RT-PCR results, the ratio of
PEX26-Dex5 transcript to full length is ∼1:2 and seemed
similar in all the tissues we examined, with the possible
exception of a lower amount in brain (fig. 4). In im-
munoblot experiments, however, we did not detect the
shorter PEX26 isoform (predicted molecular weight of
28 vs. 34 kD for full-length PEX26). This suggests that
either the shorter transcript is not translated with the
same efficiency as for the full-length transcript or the
shorter isoform of PEX26 is less stable. Additional stud-
ies determining the relative ratio of these transcripts
and the amount of the short PEX26 isoform in various
cells and tissues in response to metabolic and/or devel-
opmental perturbations will be required to determine
potential physiologic consequences of this alternative
splicing.
The other alternatively spliced PEX26 transcript we
tested, PEX26-Dex2, lacks the normal translation start
site and did not encode a functional PEX26 isoform.
This result indicates that translation initiation at the
most N-terminal internal methionine (Met96) either
does not occur or produces an N-terminal–truncated
protein that is unstable and/or nonfunctional. We favor
the latter possibility. Met96 has an apparently accept-
able Kozak consensus and might reasonably be expected
to initiate translation. However, our functional studies
(see below) and the N-terminal clustering of conserved
sequence blocks and disease-producing missense muta-
tions indicate that the N-terminus of PEX26 is essential
for its function. These observations and conclusions
contrast with those of Matsumoto et al., who report
some residual activity for the PEX26-M1T allele ex-
pressed in PEX26-deficient CHO cells (ZP167) (Mat-
sumoto et al. 2003b). The explanation for this differ-
ence is not clear, except possibly that the M1T transcript
and/or its protein product behave differently in the
CHO cell environment, as compared with our experi-
ments in patient fibroblasts.
What do these results say about PEX26 function?
First, our C- and N-terminal truncation studies of
PEX26, mislocalized to the nucleus, delimit the PEX6-
binding domain of PEX26 to the N-terminal half of the
protein (residues 29–163). This result is consistent with
the higher degree of sequence conservation among the
vertebrate PEX26 orthologs in this segment of the pro-
tein and with the clustering of the disease-producing
missense mutation to the same region. Moreover, our
functional studies show that the minimal segment of
PEX26 required to rescue peroxisome biogenesis in
CG8 cells (residues 2–174) corresponds almost precisely
to the minimal segment required for PEX6 binding. Ad-
ditionally, we find that PEX26 undergoes alternative
splicing, and, surprisingly, a splice form lacking the trans-
membrane (PEX26-Dex5) is fully functional, despite a
cytosolic rather than peroxisomal location. The conclu-
sion that PEX26 does not require peroxisomal location
to restore biogenesis is substantiated by our studies with
a chimeric protein (PEX26-Mito) comprising the N-ter-
minal half of PEX26 and a C-terminal segment from a
rat mitochondrial outer membrane protein that is ex-
clusively (within the limits of detection by indirect im-
munofluorescence methods) localized to mitochondria.
In this extraperoxisomal location, PEX26-Mito seques-
ters PEX6 and a substantial fraction of PEX1 (fig. 8).
Despite the mislocalization of these peroxins, we find
that peroxisome matrix-protein import is restored by
the expression of PEX26-Mito in PEX26-deficient cells
(fig. 7). Although the interaction of PEX26 with PEX6
is essential for matrix-protein import, our results indi-
cate that neither protein requires a peroxisomal location
to perform its function in peroxisome biogenesis.
Ultimately, understanding the role of PEX26 in per-
oxisome biogenesis will require better understanding of
the functions of PEX1 and PEX6. Observations in yeast
and humans suggest that these two, closely related, type
II AAA ATPases (Vale 2000; Frickey and Lupas 2004)
form a dynamic hetero-oligomeric complex whose sub-
unit interactions depend on ATP binding and whose func-
tion depends on ATP hydrolysis (Faber et al. 1998b;
Tamura et al. 1998; Kiel et al. 1999). For example, in
the yeast Pichia pastoris, PEX1 and PEX6 coimmuno-
precipitate only in the presence of ATP or ATPgS. In
this regard, PEX1 and PEX6 appear to resemble a few
AAA ATPases (e.g., VPS4 and katanin) that cycle be-
tween monomeric and oligomeric forms and contrast
to other AAA ATPases (e.g., NSF, p97) that form stable
two-tiered hexameric rings (Vale 2000). Consistent with
the hypothesis that the interaction between PEX1 and
PEX6 is dynamic, their subcellular localizations appear
to be overlapping but not identical. Using epitope-
tagged constructs with expression driven by a strong
promoter in wild-type cells, we found that PEX6 ap-
pears to be exclusively cytosolic, whereas PEX1 is mainly
cytosolic but with detectable signal also colocalizing
Weller et al.: PEX26 Alternative Splicing 1005
with peroxisomes. Similar overlapping but nonidentical
subcellular localizations were described for Pichia pas-
toris PEX1 and PEX6 (Faber et al. 1998b). Moreover,
our results with PEX26-Mito showing full restoration
of peroxisome matrix-protein import in PEX26-defi-
cient cells despite mislocalization of PEX26, PEX6, and
a fraction of PEX1 to the mitochondrial outer membrane
predict that some protein is able to move from the
PEX26-PEX6 complex on the mitochondrial outer mem-
brane to the peroxisome. PEX1 is the most obvious
candidate, given that its interaction with PEX6 appears
to be dynamic and that we find PEX1 at both mito-
chondrial and peroxisomal locations. We also speculate
that, in these mislocalization experiments, PEX1 cycles
between a location on the peroxisomal membrane and
the complex with PEX6 tethered to the mitochondrial
outer membrane by PEX26-Mito. We also speculate that
the interaction with PEX6 serves to “activate” PEX1,
perhaps through some conformational change in a man-
ner that allows it to complete its function for matrix-
protein import after it relocates to the peroxisome
membrane. This function could involve disassembly of
the matrix-protein–receptor complex or release of the
N-terminus of PEX5 from the peroxisome membrane
(Costa-Rodrigues et al. 2004) or some other, as yet un-
appreciated, function. Consistent with this model, Shio-
zawa et al. (2004) have recently examined the structure
of the NTD of PEX1 (aa 1–180). Using bioinformatics
analyses, they noted that the NTD of PEX1 but not that
of PEX6 resembles that of two other AAA ATPases,
NSF and p97. Using crystallographic studies at a 2.05-
A˚ resolution, they showed that the NTD of PEX1 folds
independently as a globular domain, with striking simi-
larities to the structure of the NTDs of NSF and p97.
On the basis of similarity to the NTDs of NSF and p97,
Shiozama et al. predict that the PEX1 NTD functions
in substrate binding and/or as a site for the binding of
a hypothetical adaptor protein. Our hypothesized “ac-
tivation” of PEX1 might involve a conformation change
in the NTD similar to those involved in the function of
NSF or p97 (Brunger and DeLaBarre 2003; Shimozawa
et al. 2004; Whiteheart and Matveeva 2004). A cor-
ollary of our model is that activated PEX1 has some
mechanism for localizing to the peroxisome membrane
independent of the PEX26-PEX6 complex, possibly by
docking to a site on one of the integral peroxisomal
membrane proteins or to a site on PEX5, which appears
to insert into the peroxisomal membrane as it delivers
peroxisomal matrix proteins to the organelle but leaves
its N-terminus exposed (Gouveia et al. 2003; Oliveira
et al. 2003; Costa-Rodrigues et al. 2004). Given that
the release of unloaded PEX5 from the organelle re-
quires ATP hydrolysis (Dodt and Gould 1996; Oliveira
et al. 2003), some interaction with PEX1 at this stage
seems likely.
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